Please ensure Javascript is enabled for purposes of website accessibility

Why TransEnterix Inc. Is Soaring Today

By Brian Feroldi - Apr 6, 2016 at 12:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Traders are bidding up shares in anticipation of an FDA approval.

Image source: TransEnterix.

What: Shares of TransEnterix (ASXC 6.21%), a small-cap medical device company that is focused on robotic surgery, rose more than 13% as of 11:30 a.m. ET today on exceptionally heavy trading volume.

So what: Once again, there doesn't appear to be any news that could help to explain the huge share price gain so it's likely that the stock is moving in anticipation of hearing good news from the Food and Drug Administration about its pending approval of the company's SurgiBot system.

Previously, TransEnterix believed that it would have a decision in hand by March, but a few weeks ago, management let investors know that the new FDA timetable called for a decision to be made by "mid-April." Shareholders have largely shrugged off the news of the delay as shares have continued to roar higher since the announcement was made.

Now what: Shares of TransEnterix have been on a huge tear so far this year, and they are currently up more than 136% year to date.

TRXC Chart

Meanwhile, the number of its shares that have been sold short have also been on the rise. There are currently about 7 million shares that have been sold short, up from only 4 million at year end. Thus, the price action over the past few weeks could be  the result of traders rushing to unwind their short position ahead of the FDA announcement. 

Regardless of the reason for today's price action, TransEnterix is in an intriguing position right now. The company's SurgiBot system promises to have a much lower up-front cost than that of industry goliath Intuitive Surgical (ISRG 0.32%), as well as a handful of other clinical advantages. Combine those factors together and it could allow the company to win over a decent number of hospital systems that have so far been unable -- or unwilling -- to pay up for Intuitive Surgical's da Vinci system.

However, that doesn't make TransEnterix's stock a slam-dunk investment, especially after its recent run. After all, the company lost more than $50 million last year and it's likely that its expenses will increase substantially over time as it invests to build out its commercial team to compete with Intuitive Surgical. That won't be cheap or easy as Intuitive employs a small army of sales reps and clinicians and rakes in billions in annual sales each year, so you can bet they will fight tooth and nail to defend their market share.

TransEnterix reported having $47.1 million in cash on their books as of February 29, 2016, which they believed would be enough to fund the company through the end of the year. That likely indicates that the company will be tapping the equity markets sometime soon to bulk up their cash supply.

Considering what has been happening with the company's share price recently, that probably isn't such a bad move, but until we know more about the FDA approval, I'm content to watch this story play out from the sidelines.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intuitive Surgical, Inc. Stock Quote
Intuitive Surgical, Inc.
$223.30 (0.32%) $0.72
Asensus Surgical, Inc. Stock Quote
Asensus Surgical, Inc.
$0.40 (6.21%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.